DUBLIN, Ohio, Jan. 20, 2005 – Cardinal Health, Inc. (NYSE: CAH), the leading provider of products and services supporting the health care industry, has reached agreement with Eisai Inc. to provide distribution services for Eisai's life-enhancing therapies.
Under terms of the multi-year contract, Cardinal Health will be paid service fees to distribute Eisai's full product line, including Aricept®, Aciphex® and Zonegran®, to hospitals and pharmacies in the U.S. via Cardinal Health's efficient network of 26 distribution centers.
"We are very pleased with the terms of this agreement and more importantly with the fact that our provider customers will continue to have low-cost access to Eisai's important product line," said Mark W. Parrish, chairman and CEO of Pharmaceutical Distribution and Provider Services for Cardinal Health. "We have created a long-term relationship that will improve the efficiency of both companies and serve our customers well, now and into the future. Our goal was to establish a fee-based agreement that provides good value for Eisai and fair compensation for Cardinal Health. With this agreement, both needs have been met with a customized distribution solution that reflects the unique requirements of Eisai's products and the value Cardinal Health provides."
"Reaching a mutually beneficial business agreement was in the best interest of those who benefit from Eisai's treatments. In addition to public announcement, pharmacy providers will be informed today that Cardinal Health will continue to supply them with the Eisai products that patients need," said Lonnel Coats, president and COO of Eisai Inc.
About Cardinal Health
Cardinal Health, Inc.(www.cardinalhealth.com) is the leading provider of products and services supporting the health care industry. Cardinal Health develops, manufactures, packages and markets products for patient care; develops drug-delivery technologies; distributes pharmaceuticals and medical, surgical and laboratory supplies; and offers consulting and other services that improve quality and efficiency in health care. Headquartered in Dublin, Ohio, Cardinal Health employs more than 55,000 people on six continents and produces annual revenues of more than $65 billion.
Except for historical information, all other information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Cardinal Health's Form 10-K, Form 8-K and Form 10-Q reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the costs, difficulties, and uncertainties related to the integration of acquired businesses, the loss of one or more key customer or supplier relationships or changes to the terms of those relationships, changes in the distribution patterns or reimbursement rates for health-care products and/or services, the results, consequences, effects or timing of any inquiry or investigation by any regulatory authority or any legal and administrative proceedings, the impact of previously announced restatements, and general economic and market conditions. Cardinal Health undertakes no obligation to update or revise any forward-looking statement. Aricept is a registered trademark of Eisai Co., Ltd., Tokyo, Japan. Aricept® is copromoted in the US with Pfizer Inc. Aciphex is a registered trademark of Eisai Co., Ltd., Tokyo, Japan. Aciphex® is copromoted with Janssen Pharmaceutica Inc. Zonegran® is a registered trademark of Dainippon Pharmaceutical Co., Ltd., Osaka, Japan, and licensed exclusively to Eisai Inc.